newsfilter
← Latest News
GlobeNewswire·

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has